Annals of Colorectal Research

Published by: Kowsar

Evaluation of the Potential Antioxidant Role of High-Density Lipoprotein-Cholesterol (HDL-C) in Patients with Ulcerative Colitis

Mostafa Vaghari Tabari 1 , 2 , Soheila Moein 1 , 2 , * , Durdi Qujeq 3 , 4 , ** , Mehrdad Kashifard 5 , Javaad Shokri Shirvani 5 , Karimollah Hajian Tilaki 6 and Gholamreza Farshidfar 2
Authors Information
1 Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
2 Department of Biochemistry, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
3 Department of Clinical Biochemistry, Babol University of Medical Sciences, Babol, Iran
4 Cellular and Molecular Biology Research Center (CMBRC), Health Research Institute, Babol University of Medical Sciences, Babol, Iran
5 Department of Internal Medicine, Gastroenterology Division, Ayatollah Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran
6 Departments of Biostatistics and Epidemiology, Babol University of Medical Sciences, Babol, Iran
Corresponding Authors:
Article information
  • Annals of Colorectal Research: September 2017, 5 (3-4); e13699
  • Published Online: June 30, 2017
  • Article Type: Research Article
  • Received: April 8, 2017
  • Accepted: May 20, 2017
  • DOI: 10.5812/acr.13699

To Cite: Vaghari Tabari M, Moein S, Qujeq D, Kashifard M, Shokri Shirvani J, et al. Evaluation of the Potential Antioxidant Role of High-Density Lipoprotein-Cholesterol (HDL-C) in Patients with Ulcerative Colitis, Ann Colorectal Res. 2017 ; 5(3-4):e13699. doi: 10.5812/acr.13699.

Abstract
Copyright © 2017, Annals of Colorectal Research. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713-25. doi: 10.1056/NEJMra1102942. [PubMed: 22047562].
  • 2. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066-78. doi: 10.1056/NEJMra0804647. [PubMed: 19923578].
  • 3. Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol. 2008;6(1):41-5. doi: 10.1016/j.cgh.2007.09.016. [PubMed: 18063423].
  • 4. Caliskan Z, Gokturk HS, Caliskan M, Gullu H, Ciftci O, Ozgur GT, et al. Impaired coronary microvascular and left ventricular diastolic function in patients with inflammatory bowel disease. Microvasc Res. 2015;97:25-30. doi: 10.1016/j.mvr.2014.08.003. [PubMed: 25128749].
  • 5. Kristensen SL, Ahlehoff O, Lindhardsen J, Erichsen R, Jensen GV, Torp-Pedersen C, et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death--a Danish nationwide cohort study. PLoS One. 2013;8(2):56944. doi: 10.1371/journal.pone.0056944. [PubMed: 23457642].
  • 6. Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011;106(4):741-7. doi: 10.1038/ajg.2011.63. [PubMed: 21386828].
  • 7. de Fatima Adorne E, Bodanese LC. Evaluation of lipid profile in patients with inflammatory bowel disease. Sci Med. 2016;26(2):22964.
  • 8. Ripolles Piquer B, Nazih H, Bourreille A, Segain JP, Huvelin JM, Galmiche JP, et al. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism. 2006;55(7):980-8. doi: 10.1016/j.metabol.2006.03.006. [PubMed: 16784973].
  • 9. Romanato G, Scarpa M, Angriman I, Faggian D, Ruffolo C, Marin R, et al. Plasma lipids and inflammation in active inflammatory bowel diseases. Aliment Pharmacol Ther. 2009;29(3):298-307. doi: 10.1111/j.1365-2036.2008.03886.x. [PubMed: 19035968].
  • 10. Sappati Biyyani RS, Putka BS, Mullen KD. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. J Clin Lipidol. 2010;4(6):478-82. doi: 10.1016/j.jacl.2010.08.021. [PubMed: 21122694].
  • 11. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. 2000;41(9):1495-508. [PubMed: 10974057].
  • 12. Baskol G, Baskol M, Yurci A, Ozbakir O, Yucesoy M. Serum paraoxonase 1 activity and malondialdehyde levels in patients with ulcerative colitis. Cell Biochem Funct. 2006;24(3):283-6. doi: 10.1002/cbf.1224. [PubMed: 15830398].
  • 13. Baskol M, Baskol G, Kocer D, Ozbakir O, Yucesoy M. Advanced oxidation protein products: a novel marker of oxidative stress in ulcerative colitis. J Clin Gastroenterol. 2008;42(6):687-91. doi: 10.1097/MCG.0b013e318074f91f. [PubMed: 18574392].
  • 14. Achitei D, Ciobica A, Balan G, Gologan E, Stanciu C, Stefanescu G. Different profile of peripheral antioxidant enzymes and lipid peroxidation in active and non-active inflammatory bowel disease patients. Dig Dis Sci. 2013;58(5):1244-9. doi: 10.1007/s10620-012-2510-z. [PubMed: 23306840].
  • 15. Tuzun A, Erdil A, Inal V, Aydin A, Bagci S, Yesilova Z, et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin Biochem. 2002;35(7):569-72. [PubMed: 12493587].
  • 16. Lodovici M, Bigagli E, Bardini G, Rotella CM. Lipoperoxidation and antioxidant capacity in patients with poorly controlled type 2 diabetes. Toxicol Ind Health. 2009;25(4-5):337-41. doi: 10.1177/0748233709106464. [PubMed: 19651806].
  • 17. Ali-Panah Mogadam R, Nemati A , Naghizadeh Baghi A. Serum MDA as a diagnostics biomarker in stable coronary heart disease. Res J Biological Sci. 2008;3(2):206-10.
  • 18. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21(4):481-8. [PubMed: 11304461].
  • 19. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330(26):1841-5. doi: 10.1056/NEJM199406303302601. [PubMed: 8196726].
  • 20. Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19(2):332-41. doi: 10.1097/MIB.0b013e3182810066. [PubMed: 23328771].
  • 21. Moein S, Qujeq D, Vaghari Tabari M, Kashifard M, Hajian K. Diagnostic accuracy of fecal calprotectin in assessing the severity of inflammatory bowel disease: From laboratory to clinic. Caspian J Intern Med. 2017;8(3):178-82.
  • 22. Yoshino T, Yamakawa K, Nishimura S, Watanabe K, Yazumi S. The predictive variable regarding relapse in patients with ulcerative colitis after achieving endoscopic mucosal healing. Intest Res. 2016;14(1):37-42. doi: 10.5217/ir.2016.14.1.37. [PubMed: 26884733].
  • 23. Qujeq D, Bijani K, Kalavi K, Mohiti J, Aliakbarpour H. Effects of Ramadan fasting on serum low-density and high-density lipoprotein-cholesterol concentrations. Ann Saudi Med. 2002;22(5-6):297-9. [PubMed: 17146246].
  • 24. Moore K, Roberts L2. Measurement of lipid peroxidation. Free Radic Res. 1998;28(6):659-71. [PubMed: 9736317].
  • 25. Qujeq D, Aliakbarpour HR, Kalavi K. Relationship between malondialdehyde level and glutathione peroxidase activity in diabetic rats. Clin Chim Acta. 2004;340(1-2):79-83. [PubMed: 14734198].
  • 26. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756-70. doi: 10.1016/S0140-6736(16)32126-2. [PubMed: 27914657].
  • 27. Actis GC. Biologics for ulcerative colitis: Status of the art and general considerations. Ann Colorectal Res. 2017;5(1).
  • 28. Mohammadi E, Qujeq D, Taheri H, Hajian-Tilaki K. Evaluation of Serum Trace Element Levels and Superoxide Dismutase Activity in Patients with Inflammatory Bowel Disease: Translating Basic Research into Clinical Application. Biol Trace Elem Res. 2017;177(2):235-40. doi: 10.1007/s12011-016-0891-0. [PubMed: 27864666].
  • 29. Moura FA, de Andrade KQ, de Araujo OR, Nunes-Souza V, Santos JC, Rabelo LA, et al. Colonic and hepatic modulation by lipoic acid and/or n-acetylcysteine supplementation in mild ulcerative colitis induced by dextran sodium sulfate in rats. Oxid Med Cell Longev. 2016;2016:4047362. doi: 10.1155/2016/4047362. [PubMed: 27957238].
  • 30. Papadimitraki ED, Ahamed M, Bunce NH. Acute myocardial infarction complicating active ulcerative colitis: a case report. Case Rep Cardiol. 2011;2011:876896. doi: 10.1155/2011/876896. [PubMed: 24826231].
  • 31. Catapano AL, Pirillo A, Bonacina F, Norata GD. HDL in innate and adaptive immunity. Cardiovasc Res. 2014;103(3):372-83. doi: 10.1093/cvr/cvu150. [PubMed: 24935428].
  • 32. Rea WE, Durrant DC, Boldy DA. Ulcerative colitis after statin treatment. Postgrad Med J. 2002;78(919):286-7. [PubMed: 12151572].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments